調査・レポート

Bill Gates reflects on his father’s Alzheimer’s care, emphasizing the human element that cannot be replaced by robots.

Brazilian researchers found that walking at least 1,000 steps a day can improve respiratory symptoms and quality of life in moderate to severe asthma patients, comparable to regular aerobic exercise.

ICCA releases J.06.01 and J.06.02 alerts that auto‑charting of infusion‑pump data can produce incorrect intake, output, net body balance and LOS balance values for units using auto charting settings.

A study published in Cell Reports shows that late‑night snacking and irregular meals alter liver enzyme activity, affecting glucose control, lipid metabolism and autophagy.

A large real‑world data analysis of 31,686 U.S. adults aged 55+ shows that continued obesity medication use reduces hospital and ER visits, leading to substantial overall cost savings.

Hanmi Pharmaceutical will unveil Phase 2 results of EPeglucoagon (HM15136), the first weekly‑dose therapy for congenital hyperinsulinism, at the ESPE 2026 meeting in Marseille.

Korean researchers report that people with diabetes show more pronounced cerebrovascular dysfunction when exposed to ultrafine particles, suggesting increased vulnerability to vascular damage.

Korea Disease Control Agency will revamp TB strain genotyping using whole-genome sequencing to better identify transmission links, aiming to meet the 2027 target of <20 cases per 100,000.

A Korean cohort of about 46,800 cancer patients showed that quitting smoking after diagnosis reduces overall death risk, with a larger benefit for cardiovascular events.

A new study from Marshall University published in Molecular Psychiatry shows that heavy drinking during youth damages astrocytes, leading to lasting anxiety and fear disorders in adulthood.

HuBase and the Pharmaceutical Policy Research Institute have signed an agreement to share pharmacy‑generated data for joint research aimed at informing drug policy and system improvements in Korea.

HLB BioStep and organoid specialist Nexel signed an MOU to combine hiPSC‑derived organoid toxicity/efficacy data with HLB’s nonclinical testing, creating an integrated evaluation service for pharma and biotech firms.